201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 224
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Richard D. Klausner M.D. | Founder & Executive Chairman | 80k | N/D | 1952 |
Dr. Lynn Seely M.D., Ph.D. | President, CEO & Director | 430.69k | N/D | 1959 |
Mr. Stephen J. Hill | Chief Operating Officer | 1.04M | N/D | 1970 |
Dr. Gary Lee Ph.D. | Chief Scientific Officer | 639.91k | N/D | 1977 |
Ms. Elizabeth Homans | Consultant | 1.99M | N/D | 1966 |
Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor | N/D | N/D | N/D |
Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor | N/D | N/D | 1961 |
Nellie Dillery | Director of Accounting | N/D | N/D | N/D |
Ms. Ellen Rose | Senior Vice President of Communications & Investor Relations | N/D | N/D | N/D |
Mr. Matthew Lang J.D. | Chief Business Officer, Chief Legal Officer & Corporate Secretary | N/D | N/D | 1976 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
La calificación ISS Governance QuickScore de Lyell Immunopharma, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 3; Junta: 7; Derechos del accionista: 8; Compensación: 9.